market access strategy

9.4.2014 Account Strategy for Payer Organizations

Managing Payer Relationships: Making Your Own Luck by Planning and Strategizing

By Natalie DeMasi, Research Analyst The key to managing payer relationships lies in Thomas Jefferson’s old adage:  "I am a great believer in luck, and I find the harder I work, the more I have of it."  Like Jefferson, managed markets account...
 

8.4.2014

Embracing Pharmaceutical PRO Metrics to Support Regulatory Approval and Product Reimbursement

For a product to succeed in today’s commercial landscape, pharma companies must be able to prove its value during regulatory and market access discussions.  Pharmaceutical PRO metrics offer both clinical teams and regulatory agencies a complete picture of a...
 

7.31.2014 Lifecycle Management

Biosimilars, Biobetters and Captain America: The Future of Biosimilars in a Future World of Biobetters

By Natalie DeMasi, Research Analyst After being untouchable for decades, US biologics companies are finally facing biosimilar competition.  Well, sort of.  Cutting Edge Information’s report on counter-generics strategies found that the high...
 

7.23.2014 Marketing

Possibilities Abound for Big Data in Pharma

By Ryan McGuire, Head of Research The uses for Big Data in pharma are limitless.  Commercial, clinical and market access teams can all benefit from Big Data insights.  With so many options, it’s no wonder some companies get decision paralysis...
 

7.15.2014 Account Strategy for Payer Organizations

Delivering a Payer Value Proposition in Managed Markets: The Role of MSLs, MCLs and HOLs

By Natalie DeMasi, Research Analyst In this era of increasing healthcare spending scrutiny, the onus is on managed markets account managers to deliver a persuasive payer value proposition.  In meetings about formularies, payers will want to see...
 

7.9.2014 Health Economics and Outcomes Research (HEOR)

Protecting Profitability: Translating Strong Health Economics and Outcomes Research to Drive Interactions with Medical Device Payers and More

By Victoria Cavicchi, Research Analyst Health economics and outcomes research (HEOR) groups have carved out their place in life sciences organizations throughout the industry. Though pharmaceutical and biotech companies have long-since accepted...
 

6.10.2014 Account Strategy for Payer Organizations

Pharmaceutical Reimbursement Strategy: What We Can All Learn From Winnie the Pooh

By Jacob Presson, Senior Research Analyst Working with payers and hospitals in order to maintain profitability is a key role for managed markets groups and the account managers responsible for these contacts. Payers are becoming increasingly interested...
 

3.24.2014 Market Access

Patient-Reported Outcomes Spurred by Big Data in Pharma

By Nicole May, Research Analyst The opportunities are countless for Big Data in pharma, particularly within the clinical trial space.  Harnessing the data generated during clinical trials could help shorten trial timelines and lead to less expensive...
 

2.26.2014 Account Strategy for Payer Organizations

Provide a Framework for New Product Planning Groups to Influence Clinical Trials

By Jacob Presson, Research Analyst A common theme running through a lot of what we at Cutting Edge Information learn while conducting research on the pharmaceutical industry is the need for more consistent and productive communication between internal...
 

11.7.2013 Health Economics and Outcomes Research (HEOR)

HEORs and Tails: Why Is Staffing Market Access Teams So Difficult?

By Christie Shilling, Research Analyst Pharmaceutical market access teams hold a wide range of responsibilities and, as such, require employees with a variety of knowledge and skills.  Organizations that create a well-rounded market access team...